Nivolumab

Who we are

  • January 9, 2024
    Efficacy and Safety of Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI Metastatic Colorectal Cancer ( NIPISAFE )
  • January 9, 2024
    Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
  • January 19, 2023
    Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer
  • December 8, 2022
    Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
  • April 5, 2022
    A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer
  • April 5, 2022
    A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
  • April 5, 2022
    A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
  • April 5, 2022
    Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients
  • April 5, 2022
    The Drug Rediscovery Protocol (DRUP Trial)
  • April 5, 2022
    The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy